• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The open AIDS journal >Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
【24h】

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

机译：阿巴卡韦/拉米夫定/齐多夫定加替诺福韦在HBV / HIV-1合并感染成人中的疗效和安全性：48周数据

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In HBV/HIV-coinfected patients, the risk of end-stage liver disease and death is increased. This open-label, prospective, pilot study evaluated abacavir/lamivudine/zidovudine twice daily plus tenofovir once daily in HBV/HIV-coinfected antiretroviral-na?ve subjects. Nine adults (8 males) enrolled, with baseline mean HIV-1 RNA = 4.5 log10 copies/mL, HBV DNA = 9.0 log10 copies/mL, and median CD4 count =158 cells/mm3. No subject had baseline ALT >5x ULN.Six subjects completed the study: 1 withdrew due to non-treatment-related toxoplasmosis and 2 were lost-to-follow-up. At week 48, 100% (6/6) of remaining subjects had ≥2 log10 decrease in HBV DNA, and 100% (6/6) and 83% (5/6) had HIV-1 RNA <400 and <50 copies/mL, respectively. Median change from baseline in CD4 count was 157 cells/mm3. One subject experienced treatment-related grade 3 leukopenia. These results demonstrate that abacavir/lamivudine/zidovudine and tenofovir were well tolerated with sustained HIV-1 and HBV antiviral activity through 48 weeks in HBV/HIV-coinfected, antiretroviral-na?ve subjects.
机译：在HBV / HIV合并感染的患者中，晚期肝病和死亡的风险增加。这项开放性，前瞻性，前瞻性研究在HBV / HIV感染的抗逆转录病毒初治受试者中，每天两次评估阿巴卡韦/拉米夫定/齐多夫定加替诺福韦一次。纳入9名成人（8名男性），基线平均HIV-1 RNA = 4.5 log10个拷贝/ mL，HBV DNA = 9.0 log10个拷贝/ mL，中位数CD4计数= 158个细胞/ mm3。没有受试者的基线ALT> 5倍ULN。六位受试者完成了研究：1位因与治疗无关的弓形虫病退出，而2位则失去随访。在第48周时，剩余受试者中100％（6/6）的HBV DNA下降≥2log10，而HIV-1 RNA <400和<50拷贝的100％（6/6）和83％（5/6） / mL。 CD4计数相对于基线的中位数变化为157个细胞/ mm3。一名受试者经历了与治疗相关的3级白细胞减少症。这些结果表明，在HBV / HIV合并感染的抗逆转录病毒初治受试者中，阿巴卡韦/拉米夫定/齐多夫定和替诺福韦在48周内具有持续的HIV-1和HBV抗病毒活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号